Varvara Karagkiozaki

Abstract:

Cardiovascular diseases constitute a major public health concern in industrialized world. Nanomedicine provides a new paradigm of rational delivery of therapeutic and diagnostic agents to the diseased sites that renders site specific therapy. In the case of atherosclerosis, the detection of vulnerable plaques that are prone to rupture is a challenge that needs to be addressed for the reduction of incidence of heart attack and stroke in younger patients. This talk focuses on Nanomedical strategies targeting atherosclerosis and potential molecular targets within the atherosclerotic plaques to regress their progression. An overview of the diversity of the nanoparticulate systems with surface ligands targeted for macrophages and other cell types of the vulnerable plaques will be given in line with drug delivery systems that elicit anti-inflammatory/-oxidant drugs. Tissue regeneration activities are essential for dealing with the late stent thrombosis of drug eluting stents (DES) that it is mainly caused by delayed endothelialization. These new perspectives under the implementation of nanomedicine aimed for atherosclerosis will be highlighted providing intelligent solutions for atherosclerosis accurate diagnosis and effective therapy. Relevant Publications 1. Karagkiozaki V. Nanomedicine Highlights in Atherosclerosis: A Review.,J. Nanopart. Res. 2013; 15:1529. 2. Karagkiozaki V, Logothetidis S et al. Nanomedicine for Atherosclerosis: Molecular Imaging. and Treatment. J Biomed Nanotechnol. 2015;11(2):191-210. 3. Karagkiozaki V. Horizons in Clinical Nanomedicine Book, Ed. V. Karagkiozaki and S. Logothetidis, Pan Stanford Publishing, 2014.